The $160 million acquisition of a FibroGen subsidiary expands AstraZeneca’s foothold in China while the company works through ...

AstraZeneca will gain full rights for roxadustat in China where it is approved to treat anaemia seen with chronic kidney ...

AstraZeneca is paying $160 million for FibroGen’s China business, giving the U.K.-based Big Pharma the regional rights to ...

AstraZeneca will buy U.S. biotech firm FibroGen's China unit for about $160 million, in its latest deal to boost its presence ...

FibroGen today announced the sale of its China subsidiary to UK pharma major AstraZeneca for around $160 million, with the ...

FibroGen sells its China unit to AstraZeneca for $160 million, extending its cash runway into 2027 and advancing its ...

By selling its China business to AstraZeneca, FibroGen can focus on developing a prostate cancer drug and potentially ...

Feb 20 (Reuters) - AstraZeneca (AZN.L), opens new tab will buy longtime partner FibroGen's (FGEN.O), opens new tab China unit for about $160 million to gain rights to its anemia drug in the ...

The $160 million acquisition of a FibroGen subsidiary expands AstraZeneca’s foothold in China while the company works through government investigations into its business practices there. AstraZeneca ...

AstraZeneca walked away from the bulk of its roxadustat partnership with FibroGen—though the pharma at the time decided to retain its relationship with the biotech’s China operations.

AstraZeneca (AZN) is set to acquire U.S. biotech company FibroGen’s (FGEN) China unit for $160 million to expand its presence in the country.